Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

"Honestly, I'm quite alarmed by what we see in the U.S. now," Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk President and CEO Lars Fruergaard Jorgensen, shown testifying on Capitol Hill in September, is warning about potential risks from compounded versions of the drug semaglutide.